Sign Out
Melanoma: Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see Pharmacology: Pharmacodynamics under Actions).
Non-small cell lung cancer (NSCLC): Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
